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g.2012.0Abstract Genome-wide patterns of variation across individuals provide most powerful source of
data for uncovering the history of migration, expansion, and adaptation of the human population.
The arrival of new technologies that type more than millions of the single nucleotide polymor-
phisms (SNPs) in a single experiment has made SNP in genome-wide association (GWA) assay a
prudent venture. SNPs represent the most widespread type of sequence variation in genomes,
and known as valuable genetic markers for revealing the evolutionary history and common genetic
polymorphisms that explain the heritable risk for common diseases. Characterizing the nature of
gene variation in human populations and assembling an extensive catalog of SNPs in candidate
genes in association with particular diseases are the major goals of human genetics. In this article
we explore the recent discovery of SNP–GWA to revolutionize not only the process of genetic var-
iation and disease detection but also the convention of preventative and curative medicine for future
prospects.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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Genome-wide data sets are increasingly being used to identify
biological pathways and networks underlying complex diseases
and in drug development process (Fig. 1). In particular, ana-
lyzing genomic data through sets deﬁned by functional path-
ways offers the potential of greater power for discovery and
natural connections to biological mechanisms. Much of genet-
ic variation in the human genome is in the form of SNPs which
is the result of point mutations that produce single base-pair
differences (substitutions or deletions) among chromosome
sequences. There are many laboratories and computational ap-
proaches to ﬁnding single nucleotide polymorphisms (SNPs)
within a genome, but all involve some form of comparative
analysis of the same DNA segment from different individuals
or from different haplotypes. SNP identiﬁcation can be based
on expressed sequence tags (ESTs), which are generated by sin-
gle-run sequencing of cDNAs obtained from different individ-
uals and assembly of overlapping sequences for the same
region permits novel SNP discoveries. The non-coding SNPs
can be classiﬁed according to whether they are found in gene
regulating segments of the genome. Many complex diseases
may arise from quantitative, rather than qualitative, differ-
ences in gene products. Coding SNPs can be classiﬁed as toGeneral method
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Figure 1 Selection of SNP made through three different pathways (ap
development with some advantages and limitations [105–113].whether they alter the sequence of the protein encoded by
the altered gene. Changes that alter protein sequences can be
classiﬁed by their effects on protein structure [1].
GWA studies have become an important tool for discovering
susceptibility genes for complex diseases. Information, includ-
ing genotype frequencies, linkage disequilibrium (LD), and
recombination rates, across populations help researchers to
conduct GWA analysis using millions of SNP markers. The
differences in association results among populations for pheno-
types of interest are partially explained byHapMap information
such as population speciﬁc common variants and linkage dis-
equilibrium blocks [2,3]. Moreover, the phased haplotypes of
HapMap samples are used as a reference for imputing untyped
markers. One million SNPs can be increased to up to 2.5 million
by imputing haplotypes from HapMap phased haplotypes
based on the pattern of observed genotypes [4].
2. SNPs in human population and concerning issues
GWA studies build directly on recent efforts to map the pat-
terns of inheritance for the most common form of genomic
variation by the use of SNPs [5]. An estimated 10 million com-
mon SNPs, those with a minor-allele frequency of at least 5%,
are transmitted across generations in blocks, allowing a fews in SNP selection
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ay reveal 
s related to drug 
 studies have 
 associations of 
 response and 
an be explored, 
 polygenetic 
Selected SNPs based on a 
description of pathways 
regarding the mechanism of 
action and pharmacokinetics of 
the drug can be easily studied. In 
complex  genetic diseases overall 
vulnerability is observed 
clinically. 
s may arise 
iscrepancy 
 errors (false-
) and 
djusted type II 
gative results) in 
sociated SNP.
By applying the pathway gene 
approach fewer false-positive 
results will be found than with 
the genome-wide method owing 
to the limitation of multiple 
testing. 
proaches) exploring the mechanism of genome variation and drug
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variation within each block [6]. Rapid advances in technology
and quality control now permit affordable, reliable genotyping
of up to 1 million SNPs in a single scan of a person’s DNA [7].
Genotyping hundreds of thousands of SNPs has led to a great
accuracy with new models and approaches in inferring popula-
tion structure, thus reconstructing population histories from
given SNPs data [8].
A complication of genome wide association studies is the
enormous number of tests of association required (at least
one per SNP); thresholds of statistical signiﬁcance are strin-
gent, making it necessary to work with very large samples
[9]. One frequently used approach to managing size is the
tiered design, in which a subset of SNPs found to be signiﬁcant
in the GWA study (sometimes called the discovery set) is gen-
otyped in a second tier (a replication set), yielding a smaller
subset of signiﬁcantly associated SNPs that are then tested in
a third tier (a second replication set), and so on [10,11]. This
process helps to identify false positive associations. Carrying
forward a large number of SNPs identiﬁed through a GWA
study into a test of replication also minimizes false negative re-
sults [12], while raising the bar for the establishment of true po-
sitive results. The pooling of results obtained in GWA studies
(Fig. 2) under the auspices of large consortia is often requiredPromoter
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expression. Several examples of the effects of SNPs on mRNA, translfor the detection of variants with small effects on the risk of
disease. Such pooled studies, like all genetic association stud-
ies, must be examined and controlled for differences in allele
frequency between groups that can lead to spurious (false po-
sitive) associations [13].
3. SNPs reveal functional polymorphism
Regulatory polymorphisms at DNA level can potentially cause
variations in gene expression. A SNP in a regulatory DNA
binding site may alter the afﬁnity with the regulatory protein,
resulting in different gene expressions as shown in Fig. 2. SNPs
in the osteopontin promoter have been shown to modify DNA
binding afﬁnity to transcription factors SP1/SP3 [14]. A GWA
study revealed a G-to-A substitution in the 5_ untranslated re-
gion (5_-UTR) of the FOXE1 gene to associate with thyroid
cancer susceptibility [15]. The T-to-C substitution located in
the 5_-UTR of the GDF5 gene causes a different interaction
with DEAF-1, a trans-acting factor for GDF5, leading to a
reduced gene expression [16].
Opioid receptors (mainly l-, d- and j-receptors) in the
endogenous opioid system regulate neuronal activity via neu-
rotransmission or neuromodulation. Variation in opioid recep-
tor genes may change the expression level or activity of opioidPromoter
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126 M. Fareed, M. Afzalreceptors, leading to increased risk for drug or alcohol depen-
dence. The minor G-allele of SNP rs569356 may enhance tran-
scription factor binding and increase d-opioid receptor gene
(OPRD1) expression [17].
At the protein and post-translational levels, variation in
protein stability due to SNPs in coding sequences can cause
different levels of enzyme activities. Thiopurine S-methyltrans-
ferase (TPMT) catalyzes the S-methylation of thiopurine
drugs. Several human TPMT variant alleles that alter the en-
coded amino acid sequence of the enzyme generate less stable
proteins [18]. Therefore, patients with those alleles have very
low TPMT activity and suffer severe, life-threatening drug tox-
icity when treated with ‘‘standard’’ doses of thiopurine drugs
[19]. The l opioid receptors (MOPRs), belonging to the seven
transmembrane receptor (7TMR) family [also called the G
protein-coupled receptor (GPCR) family], mediate the
pharmacological effects of morphine and other l-preferring
compounds. Activation of the MOPRs produces analgesia, re-
ward, mood changes, sedation, respiratory depression, immu-
nosuppression, decreased gastrointestinal motility, increased
locomotor activity, tolerance and dependence. A common
A118G SNP reduces MOPR N-glycosylation and protein sta-
bility [20].
Non-synonymous SNPs can affect post-translational mod-
iﬁcations. Because protein phosphorylation is one of the key
elements in signal transduction, an altered phosphorylation
pattern can cause different responses to the environment.
The human ether-a-go-go-related gene 1 (ERG1) protein chan-
nel polymorphism is associated with cardiac arrhythmias [21].
A SNP leading to a Lys897Thr substitution creates a phos-Table 1 GWA studies showing SNPs association with cancer.
Disease Chromosomal
location
Gene
Breast cancer 10q26.13 FGFR2
16q12.1 TNCR9/LOC643714
5q11.2 MAP3K1
11p15.5 LSP1
8q24.21 Intergenic
2q34 ERBB4
10q26.13 FGFR2
2q35 Intergenic
Basal cell carcinoma 1q42.13 RHOU
1p36.13 PADI4, PADI6, RCC2, ARHGEF
12q12.13 KRT5
9p21 CDKN2A/B
8q24.21 Intergenic
8q24.21 Intergenic
17q12 TCF2
11p15 IGF2, IGF2A, INS, TH
Colorectal cancer 8q24.21 ORF, DQ515897
18q21.1 SMAD7
Lung cancer 15q25.1 CHRNA3, CHRNA5, CHRNB4,
6p22.1 TRNAA-UGC
Melanoma 20q11.22 CDC91L1
22q13.1 Intergenic
Neuroblastoma 6p22.3 FLJ22536, FLJ44180
2q35 BARD1
Ovarian cancer 9p22.2 Intergenic
Thyroid cancer 9q22.23 FOXE1
14q13.3 NKX2-1phorylation site in ERG1, which in turn inhibits channel activ-
ity for the downstream signal transduction [22].
4. GWA study in human disease
GWA studies in which hundreds of thousands of single-nucle-
otide polymorphisms (SNPs) are tested for association with a
disease in hundreds or thousands of persons have revolution-
ized the search for genetic inﬂuences on complex traits
[23,24]. Such conditions, in contrast with single-gene disorders,
are caused by many genetic and environmental factors work-
ing together, each having a relatively small effect and few if
any being absolutely required for a disease to occur. Although
complex conditions have been referred to as the geneticist’s
nightmare [25], in recent years GWA studies have identiﬁed
SNPs implicating more than hundreds of robustly replicated
loci for common diseases such as cancer, infectious diseases
and many other traits shown in Tables 1–3 respectively.
GWA studies use dense maps of SNPs covering the human
genome to look for allelic frequency differences between the
cases (patients with a speciﬁc disease or individuals with a cer-
tain trait) and controls. Linkage disequilibrium (LD) mapping,
recognizes that a mutation which is shared by affected individ-
uals through common descent is surrounded by other alleles at
nearby loci, thus representing the haplotype of the ancestral
chromosome region where the mutation ﬁrst occurred. Two
polymorphic sites are said to be in LD when their speciﬁc al-
leles are correlated in a population. High LD means that the
SNP alleles are almost always inherited together; information
about the allele of one SNP in an individual is stronglyStrongest SNPs-risk
allele
P-value Reference
rs2981582-G 2 · 1076 [11,36-38]
rs3803662-C 1 · 1036
rs889312-A 7 · 1020
rs3817198-T 3 · 109
rs13281615-T 5 · 1012
rs13393577-C/T 8.8 · 1014
rs1219648-G 1 · 1010
rs13387042-A 1 · 1013
rs801114-G 6 · 1012 [39-44]
10L rs7538876-A 4 · 1012
rs11170164-A 2 · 109
rs2151280-C 7 · 109
rs16901979-A 1 · 1012
rs6983267-G 9 · 1013
rs4430796-A 1 · 1011
rs7127900-A 3 · 1033
rs10505477-A 3 · 1011 [45,46]
rs4939827-T 1 · 1012
PSMA4, LOC123688 rs8034191-C 5 · 1020 [47]
rs4324798-A 2 · 108 [48]
rs910873-T 1 · 1015 [49,50]
rs2284063-G 2 · 109
rs6939340-G 9 · 1015 [51,52]
rs6435862-G 9 · 1018
rs3814113-T 5 · 1019 [53]
rs965513-A 2 · 1027 [15]
rs944289-T 2 · 109
Table 2 SNPs signiﬁcantly associated with infectious disease phenotypes in genome-wide studies.
Disease SNP location Strongest SNPs-risk allele P-value Reference
Creutzfeldt–Jakob disease PRNP rs1799990 2.0 · 1027 [54]
Dengue shock Syndrome MICB rs3132468 4.4 · 1011 [55]
Hepatitis B HLA-DPA1 rs3077 2.3 · 1038 [56]
HLA-DPB1 rs9277535 6.3 · 1039
Hepatitis C IL28B rs8099917 6.1 · 109 [57]
HIV-1 and AIDS HLA-C rs9264942 5.9 · 1032 [58–64]
HLA-B, HCP5 rs2395029 4.5 · 1035
HLA-B rs2523608 5.6 · 1010
HLA-C rs9264942 2.8 · 1035
MICA rs4418214 1.4 · 1034
HLA-B, HCP5 rs2395029 9.7 · 1026
PSORS1C3 rs3131018 4.2 · 1016
HLA-B rs2523608 8.9 · 1020
Intergenic rs2255221 3.5 · 1014
HLA-B rs2523590 1.7 · 1013
Intergenic rs9262632 1.0 · 108
ZNRD1, RNF39 rs9261174 1.8 · 108
PARD3B rs11884476 3.4 · 109
HLA-B, HCP5 rs2395029 6.8 · 1010
CXCR6 rs2234358 9.7 · 1010
Leprosy LACC1 rs3764147 3.7 · 1054 [65]
NOD2 rs9302752 3.8 · 1040
RIPK2 rs42490 1.4 · 1016
CCDC122 rs3088362 1.4 · 1031
TNFSF15 rs6478108 3.4 · 1021
Meningococcal disease CFH rs1065489 2.2 · 1011 [66]
Severe malaria HBB rs11036238 3.7 · 1011 [67]
Tuberculosis 18q11.2 GATA6, TAGE1, RBBP8, CABLES1 rs4334126 6.8 · 109 [68]
Single nucleotide polymorphism in genome-wide association study 127predictive of the allele of the other SNP on that chromosome.
The ﬁrst example of LD between a DNA polymorphism and a
disease mutation was provided by an association between an
allele of an RFLP in the b-globin gene and the sickle-cell form
of hemoglobin [26].
Next-generation sequencing projects are revolutionizing
our understanding of genetic variation. The quality of data
from the next-generation technology and the availability of
analysis tools are both rapidly increasing. Just considering
the pilot data from the 1000 Genome Projects, this new re-
source has provided the location, allele frequency, and local
haplotype structure of approximately 15 million SNPs [27].
Successful GWA studies are the most visible and exciting out-
come of HapMap which has also been invaluable in developing
genotyping and analytic methods to realize advances in the
prevention and treatment of common diseases. The tool of
sequencing enables scientists to pinpoint functional variants
from association studies and improve the knowledge available
to researchers interested in evolutionary biology, and hence
may lay the foundation for predicting disease susceptibility
and drug response.5. Role of SNPs in drug development
GWAS have uncovered many genetic loci that are associated
with human diseases, but two fundamental limitations have
hampered our ability to translate these results into clinically
useful predictors of disease and drug targets [28]. The U.S.
Food and Drug Administration’s Adverse Event Reporting
System (AERS) allows us to develop an initial understandingof the context within which molecular level drug-target interac-
tions can lead to distal effectors that results in adverse pheno-
types at the organ and organismal levels [29]. Targeting drugs
for complex diseases and predicting therapeutic efﬁcacy and
adverse risk for individuals with allelic variation (like SNPs)
are the major goals of pharmacology. The allelic variants of
the genes can lead to adverse effect of drugs and open new
ways to drug development. Some of the genes related to severe
diseases with pharmacogenomic targets and recommended
drug therapy are shown in Table 4.
Drug transporters are now widely known as important
determinants governing drug absorption, excretion, and, in
many cases, extent of drug entry into target organs. Transport-
ers of the solute carrier (SLC) and ATP-binding cassette
(ABC) superfamilies are considered to be of major importance
in drug therapy and outline how understanding the expression,
function, and genetic variation in such drug transporters will
result in better strategies for optimal drug design and tissue
targeting as well as reduce the risk for drug–drug interactions
and adverse drug responses. SNPs in genes encoding Organic
cation transporters (OCTs) have been identiﬁed and character-
ized [30].
Aldehyde oxidase (AO) is a complex molybdoﬂavoprotein
that belongs to the xanthine oxidase family. Human aldehyde
oxidase (hAOX1) encoded by AOX1 gene has an important
role in the metabolism of drugs, based on its broad substrate
speciﬁcity oxidizing aromatic aza–heterocycles, e.g., N1-meth-
ylnicotinamide and N-methylphthalazinium, or aldehydes,
such as benzaldehyde, retinal and vanillin. SNP based func-
tionally inactive hAOX1 allelic variants and also variants cod-
ing for enzymes with different catalytic activities are well
128 M. Fareed, M. Afzalconsidered for the design of future drugs [31]. VKORC1
encodes the vitamin K-epoxide reductase protein, the targetTable 3 SNP-GWA association studies in various traits.
Disease/trait Chromosomal location Gene
Autoimmune diseases
Rheumatoid arthritis 2p14 SPRED2
5q11 ANKRD55,
3p14 PXK
4p15 RBPJ
3 6q27 CCR6
31 7q32 IRF5
9q34 TRAF1-C5
6q23.3 Near TNFAI
Systemic lupus erythematosus 4q24 BANK1
Cardiovascular conditions
Atrial ﬁbrillation/atrial ﬂutter 4q25 Intergenic
Near PITX2
Coronary disease 9p21.3 CDKN2A/B
9p21.3 CDKN2A/B
6q25.1 MTHFD1L
2q36.3 Pseudogene
Coronary heart disease (CHD) 9q33 DAB2IP
Myocardial 9p21.3 CDKN2A/B
Diabetes
Type 1 diabetes 19q13.33 FUT2
12q24.13 C12orf30
12q13.2 ERBB3
16p13.13 KIAA0350
18p11.21 PTPN2
18q22.2 CD226
12q13.2 ERBB3
16q13.13 TRAFD1, PT
16p13.13 KIAA0350
Type 2 diabetes 11p15 KCNQ1
8q24.11 SLC30A8
16q12.2 FTO
10q23.33 HHEX
6p22.3 CDKAL1
9p21.3 CDKN2B
3q27.2 IGFBP2
9p21.3 CDKN2A/B
3q27.2 IGF2BP2
6p22.3 CDKAL1
6p22.3 CDKAL1
9p21.3 CDKN2A/B
3q27.2 IGF2BP2
11p12 Intergenic
Gastrointestinal disorders
Celiac disease 4q27 KIA1109, TE
Crohn disease 5p13.1 Intergenic
1q24.3 Intergenic
18p11. PTPN2
3p21.31 Many genes
5q33.1 IRGM
21q22.2 Intergenic
10q24.2 NKX2–3
1q31.2 Intergenic
2q37.1 ATG16L1
3p21.31 BSN, MST1
5q33.1 IRGM
10q24.2 NKX2–3
18p11.21 PTPN2enzyme of warfarin. VKORC1 catalyzes the conversion of vita-
min K-epoxide into vitamin K, which is the rate-limiting stepStrongest risk allele P-value References
rs934734-A 3.2 · 107 [69–71]
IL6ST rs6859219-C 2.5 · 109
rs13315591-T 3.7 · 107
rs874040-G 1.9 · 107
rs309302-G 3.3 · 107
rs104886-T 2.8 · 106
rs3761847-G 1 · 1014
P3, OLIG3 rs10499194-C 1 · 109
rs10516487-G 4 · 1010 [72]
rs2200733-T 3 · 1041 [73]
rs10033464-T 7 · 1011
rs1333049-C 1 · 1013 [74,75]
rs1333049-C 3 · 1019
rs6922269-A 3 · 108
rs2943634-C 2 · 107
rs7025486-? 0.003 [76]
rs10757278-G 1 · 1020 [77]
rs601338A >G 4.3 · 1018 [74,78–80]
rs17696736-G 2 · 1016
rs2292239-A 2 · 1020
rs12708716-A 3 · 1018
rs2542151-C 1 · 1014
rs763361-A 1 · 108
rs11171739-C 1 · 1011
PN11, KIAA0350 rs12708716-A 5 · 107
rs2903692-G 7 · 1011
rs151290-? 0.002 [25,81-84]
rs13266634-C 6 · 108
rs8050136-A 1 · 1012
rs5015480-C 6 · 1010
rs10946398-C 4 · 1011
rs10811661-T 8 · 1015
rs4402960-T 9 · 1016
rs10811661-T 8 · 1015
rs4402960-T 9 · 1016
rs7754840-C 4 · 1011
rs7754840-C 4 · 1011
rs10811661-T 8 · 1015
rs4402960-T 9 · 1016
rs9300039-C 4 · 107
NR, IL2, IL21 rs6822844-G 1 · 10–14 [85]
rs1373692-? 2 · 10–12 [74,86-88]
rs12035082-? 2 · 107
rs2542151-? 3 · 108
rs9858542-? 5 · 108
rs13361189-? 2 · 1010
rs2836754-? 5 · 107
rs10883365-? 4 · 1018
rs10801047-? 3 · 108
rs2241880-G 1 · 1013
rs9858542-A 4 · 108
rs1000113-T 3 · 107
rs10883365-G 6 · 108
rs2542151-G 2 · 107
Table 3 (contiued)
Gallstones 2p24.2 ABCG8 rs11887534-C 1 · 1014 [89]
12q24.13 SH2B3/LNK rs17696736-G 2 · 1014
Inﬂammatory bowel disease 1p31 IL23R rs11209026-A 4 · 1011 [90]
Lipid metabolism
HDL-cholesterol 1q42.13 GALNT2 rs4846914-G 2 · 1013 [91,92]
12q24.11 MVK/MMAB rs2338104-G 3 · 108
LDL-cholesterol 1p13.3 CELSR2, PSRC1 rs599839-G 1 · 107 [91,93]
1p13.3 CELSR2, PSRC1, SORT1 3 · 1029
19p13.11 CILP2, PBX4 rs16996148-G 3 · 108
Triglycerides 7q11.23 BCL7B, TBL2, MLXIPL rs17145738-T 7 · 1022 [91,92,94]
19p13.11 CILP2, PBX4 rs16996148-G 4 · 109
8q24.13 TRIB1 rs17321515-A 4 · 1017
1q42.13 GALNT2 rs4846914-G 7 · 1015
1p31.3 ANGPTL3, DOCK7, ATG4C rs12130333-C 2 · 108
2p23.3 GCKR rs780094-T 6 · 1032
8q24.13 TRIB1 rs17321515-A 7 · 1013
19p13.3 NCAN/CILP2 rs16996148-G 3 · 109
7q11.23 MLXIPL rs17145738-C 2 · 1012
1p31.3 ANGPTL3 rs1748195-C 2 · 1010
7q11.23 MLXIPL rs3812316-C 1 · 1010
Neuropsychiatric conditions
Amyotrophic lateral sclerosis 7q36.2 DPP6 rs10260404-C 5 · 108 [95]
APOE*e4 with late-onset Alzheimer disease 11q14.1 GAB2 rs2373115-G 1 · 1010 [96]
Bipolar disorder 13q14.11 DGKH rs1012053-A 2 · 108 [74,97]
16p12.1 PALB2, NDUFAB1, DCTN5 rs420259-A 6 · 108
Multiple sclerosis 16p13 KIAA 0350 rs6498169-? ? [98,99]
10p15.1 IL2RA rs12722489-C 3 · 108
5p13.2 IL7RA rs6897932-C 3 · 107
Restless legs syndrome 6p21.2 BTBD9 rs3923809-A 1 · 1017 [100,101]
2p14 MEIS1 rs2300478-G 3 · 1028
6p21.2 BTBD9 rs9296249-T 4 · 1018
15q23 MAP2K5, LBXCOR1 rs12593813-G 1 · 1015
Schizophrenia Xp22.33/Yp11.32 CSF2RA rs4129148-C 4 · 107 [102]
Sporadic amyotrophic lateral sclerosis 10q26.13 Intergenic rs4363506-? 7 · 107 [103]
N/R = not reported, ? = not described.
Single nucleotide polymorphism in genome-wide association study 129in vitamin K recycling. A common non-coding variant
(1639G > A, rs9923231) is signiﬁcantly associated with
warfarin sensitivity and its polymorphism alters a VKORC1
transcription factor binding site, leading to lower protein
expression [32].
Fig. 3 represents allelic variants associated with drug-in-
duced liver injury (DILI). Pharmacogenomic study reveals
the associations between DILI susceptibility and several poly-
morphisms in various genes, such as speciﬁc alleles in manga-
nese superoxide dismutase glutathione peroxidase, and
glutathione S-transferase that are signiﬁcantly more frequent
in DILI patients than in controls and shared across multiple
drugs [33–36]. In the context of large genetic variation,
GWA studies help us in identifying SNPs as pharmacody-
namic models which can lead to develop a mechanistic under-
standing of drug action in the context of population as well as
an individual’s genomic status.6. Conclusion
Natural selection exerts its inﬂuence by changing allele fre-
quencies of polymorphic markers to eliminate a deleterious
phenotype from a population or otherwise ﬁx a beneﬁcial
one. The human complex traits as a matter of fact, show var-
iation with SNPs having adverse effects on drug exposurewhich could be lethal. Many SNPs have been explored as a
high-resolution marker for accelerating the pace of gene map-
ping related to diseases or traits. The GWA–SNPs have been
studied in different human populations and their quantiﬁca-
tion for population structure within and between the
populations has been attempted for association studies. Inter-
individual variability in drug response is inﬂuenced by varia-
tion in genes that control the absorption, distribution,
metabolism and excretion of drugs. The Wellcome Trust Case
Control Consortium (WTCCC) is engaged in exploring the
utility, design and analysis of GWA studies. The International
HapMap resource, documents patterns of genome-wide varia-
tion and linkage disequilibrium in population samples and
greatly facilitates both the design and analysis of association
studies. The availability of advance genotyping chips, contain-
ing sets of large number of SNPs provides good coverage of
the human genome, to which means that GWA studies can
be used for thousands of cases and controls for exploring the
basis of complex traits.
Identiﬁcation of the genetic basis for polymorphic expres-
sion of a gene is done through intronic or exomic SNPs which
abolishes the need for different mechanisms for explaining the
variability in drug metabolism. SNPs based variations in mem-
brane receptors lead to multidrug resistance (MDR) and the
drug–drug interactions. Even drug induced toxicity and many
adverse effects can be explained by GWA studies. The aim of
Table 4 Some genes identiﬁed by Genome-wide studies which are pharmacogenomic targets with recommended drug therapy.
Therapeutic area Gene/marker Drug involved
Allergy CYP2D6 Desloratadine, Pseudoephedrine
Analgesics CYP2D6 Codeine, Tramadol, Acetaminophen
CYP2C9 Celecoxib
Antiarrhythmics CYP2D6 Quinidine
Antifungals CYP2C19 Voriconazole
CYP2D6 Terbinaﬁne
Antiinfectives NAT1; NAT2 Rifampin, Isoniazid, Pyrazinamide
Antivirals CCR5 Maraviroc
IL28B Boceprevir
Cardiovascular ApoE2 Pravastatin
CYP2C19 Ticagrelor, Clopidogrel
CYP2D6 Metoprolol, Carvedilol, Propranolol
Dermatology and dental PML/RARa Tretinoin
DPD Fluorouracil
CYP2D6 Cevimeline
Gastroenterology UCD NAGS;
CPS; ASS; OTC;
ASL; ARG
Sodium Phenylacetate, Sodium Benzoate
CYP2C19 Rabeprazole, Esomeprazole, Pantoprazole,
Dexlansoprazole,
Hematology VKORC1 Warfarin
CYP2C9 Warfarin
Metabolic and Endocrinology LDL receptor Atorvastatin
Musculoskeletal CYP2C19 Carisoprodol
Neurology CYP2D6 Dextromethorphan, Quinidine, Tetrabenazine,
Galantamine
CYP2C19 Clobazam
HLA-B*1502 Carbamazepine
Oncology PDGFR Imatinib
PML/RARa Arsenic Trioxide
CYP2D6 Geﬁtinib
CD20 antigen Tositumomab
KRAS Cetuximab, Panitumumab
Her2/neu Lapatinib, Trastuzumab
CD30 Brentuximab Vedotin
C-Kit Imatinib
DPD Capecitabine
TPMT Mercaptopurine, Thioguanine, Cisplatin
FIP1L1-PDGFRa Imatinib
ER &/PgR
receptor
Exemestane
ER receptor Fulvestrant, Tamoxifen
Ph Chromosome Nilotinib, Dasatinib, Busulfan, Imatinib
BRAF Vemurafenib
ALK Crizotinib
EGFR Panitumumab, Cetuximab
Psychiatry UCD NAGS;
CPS; ASS; OTC;
ASL; ARG
Valproic Acid
CYP2C19 Diazepam, Citalopram, Fluvoxamine, Modaﬁnil
CYP2D6 Citalopram, Clomipramine, Desipramine,
Aripiprazole, Iloperidone, Fluoxetine, Pimozide,
Doxepin, Protriptyline, Chlordiazepoxide,
Amitriptyline, Modaﬁnil, Nefazodone, Nortriptyline,
Thioridazine, Trimipramine, Venlafaxine, Clozapine,
Risperidone, Fluoxetine, Olanzapine
Pulmonary CFTR G551D Ivacaftor
Reproductive and urologic CYP2D6 Tolterodine
Rheumatology TPMT Azathioprine
CYP2C9 Flurbiprofen
Compiled from Food and Drug Administration, 2012 [104].
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Figure 3 GWA approach to uncover SNPs for drug induced hepatotoxicity. The study has shown statistically signiﬁcant associations
with particular HLA class I or II alleles, suggesting that T cell responses contribute to the liver injury. The adverse reactions by the
corresponding SNPs against HLA genes in response to drugs are shown on the right hand side of the above ﬁgure which is compiled from
the data of some recent studies [119–122] based on GWA studies.
Single nucleotide polymorphism in genome-wide association study 131this review is to throw fresh light on human genetic variation
using SNPs to predict drug response and its wide applications
in medical, health and pharmacogenetic studies. The tool of
SNPs can help understand the alteration in the amino-acid
sequence of the encoded protein and make a common cause
of pharmacologically relevant functional variation. The multi-
tude of SNPs help in understanding gene pharmacokinetic
(PK) or pharmacodynamic (PD) pathways. The association of
a wide range of human diseases like cancer, infectious diseases
(AIDS, leprosy, hepatitis, etc.) autoimmune, neuropsychiatric
and many other diseases (Tables 1–4) with different SNPs can
bemade as relevant pharmacogenomic targets for drug therapy.
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